NEW YORK (GenomeWeb News) – Vermillion said today that its Aspira Labs subsidiary has received its clinical laboratory permit for the state of New York.

With the New York permit, Aspira is now licensed in all states requiring licensing, allowing the company to process Vermillion's OVA1 ovarian cancer test nationwide.

The permit also marks a milestone in the company's efforts to transition OVA1 testing from Quest Diagnostics to Aspira, which is a key aspect of its new commercial strategy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.